跳轉至內容
Merck
全部照片(1)

重要文件

檢視所有文件

H6132

Sigma-Aldrich

DL -3-羟基-3-甲基戊二酰辅酶 A 钠盐 水合物

≥90% (HPLC)

同義詞:

[=β-hydroxy-β-mathylglutaryl-CoA]β-羟-β-甲基戊二酸单酰辅酶A

登入查看組織和合約定價
全部照片(1)

About This Item

經驗公式（希爾表示法）:
C27H42N7Na2O20P3S · xH2O
CAS號碼:
103476-21-7
分子量：:
955.62 (anhydrous basis)
分類程式碼代碼:
41106305
PubChem物質ID:
24895729
NACRES:
NA.51

品質等級

200

化驗

≥90% (HPLC)

形狀

powder

溶解度

H2O: soluble-50 mg/mL, clear, colorless to faintly yellow

儲存溫度

−20°C

SMILES 字串

O.[Na+].[Na+].CC(O)(CC(O)=O)CC(=O)SCCNC(=O)CCNC(=O)[C@@H](O)C(C)(C)COP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1OP([O-])([O-])=O)n2cnc3c(N)ncnc23

InChI

1S/C27H44N7O20P3S.2Na.H2O/c1-26(2,21(40)24(41)30-5-4-15(35)29-6-7-58-17(38)9-27(3,42)8-16(36)37)11-51-57(48,49)54-56(46,47)50-10-14-20(53-55(43,44)45)19(39)25(52-14)34-13-33-18-22(28)31-12-32-23(18)34;;;/h12-14,19-21,25,39-40,42H,4-11H2,1-3H3,(H,29,35)(H,30,41)(H,36,37)(H,46,47)(H,48,49)(H2,28,31,32)(H2,43,44,45);;;1H2/q;2*+1;/p-2/t14-,19-,20-,21-,25-,27?;;;/m1.../s1

InChI 密鑰

QGWMCHPRNDWWMT-UAUHQYJPSA-L

相關類別

一般說明

DL-3-羟基-3-甲戊二酰辅酶A(HMG-CoA)在HMG-CoA合酶作用下由乙酰CoA和乙酰乙酰CoA缩合而成。

應用

DL-3-羟基-3-甲戊二酰辅酶A钠盐水合物已用于在药物治疗中研究其对mTORC1调控的影响。它还用于比较两种反应性酰基辅酶A（如HMG-CoA和戊二酰-CoA）的酰化蛋白组。

生化／生理作用

DL-3-羟基-3-甲戊二酰辅酶A(HMG-CoA)可作为底物用于研究3-羟基-3-甲戊二酰辅酶A(HMG-CoA)还原酶的特异性和动力学。 羟甲基戊二酰辅酶A(HMG-CoA)是萜类和酮类生物合成的关键中间体。它的代谢是他汀类药物的靶点，通过其控制胆固醇水平。
DL-3-羟基-3-甲戊二酰辅酶A(HMG-CoA)可作为胆固醇合成的前体，抑制羟甲基戊二酰辅酶A(HMG-CoA)会降低胆固醇的生成。它在血液中可转化生成β-羟基丁酸。羟甲基戊二酰辅酶A(HMG-CoA)是胆固醇生物合成的调节酶，可偶联LDL受体调节胆固醇合成，受到抑制后会降低胆固醇的生成。

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

個人防護裝備

Eyeshields, Gloves, type N95 (US)

從最近期的版本中選擇一個：

分析證明 (COA)

Lot/Batch Number
SLCJ3413
SLCC1042
SLBW4598
SLBB7996V
SLBH5208V

未看到正確版本？

如果您需要一個特定的版本，您可以透過批號來尋找特定憑證。

搜尋 COA

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Yoshiko Mizuno et al.
Journal of atherosclerosis and thrombosis, 18(5), 351-358 (2011-03-24)
Atherosclerosis is a progressive disease causally associated with multiple cardiovascular risk factors, including dyslipidemia. Without effective intervention, atherosclerosis becomes evidenced clinically as coronary artery and cerebrovascular disease, both of which remain the leading causes of death worldwide. Multiple lines of
Anti-Inflammatory Treatment
Coronary Artery Disease, 237-271 (2018)
Leucine Signals to mTORC1 via Its Metabolite Acetyl-Coenzyme A
Son SM, et al.
Cell Metabolism, 29(1), 192-201 (2019)
Sarah Statt et al.
American journal of respiratory cell and molecular biology, 53(5), 689-702 (2015-04-16)
Statins are widely used to prevent cardiovascular disease. In addition to their inhibitory effects on cholesterol synthesis, statins have beneficial effects in patients with sepsis and pneumonia, although molecular mechanisms have mostly remained unclear. Using human airway epithelial cells as
Helle Keinicke et al.
Endocrine connections, 9(8), 755-768 (2020-07-21)
The prevalence of non-alcoholic fatty liver disease (NAFLD) has increased dramatically worldwide and, subsequently, also the risk of developing non-alcoholic steatohepatitis (NASH), hepatic fibrosis, cirrhosis and cancer. Today, weight loss is the only available treatment, but administration of fibroblast growth
查看所有相關論文

文章

Dietary Terpenes

Dietary Terpenes

Cholesterol Biosynthesis

Biosynthesis of cholesterol generally takes place in the endoplasmic reticulum of hepatic cells and begins with acetyl- CoA, which is mainly derived from an oxidation reaction in the mitochondria. Acetyl-CoA and acetoacetyl-CoA are converted to 3-hydroxy- 3-methylglutaryl-CoA (HMG-CoA) by HMG-CoA synthase.

Dietary Terpenes

Terpenes comprise the largest and most diverse class of secondary metabolites; approximately 55,000 compounds have been identified to date.

Antilipemic Agents

Randomized controlled clinical studies have suggested 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are effective in both primary and secondary prevention of cardiovascular disease (CVD) events.

查看全部

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務